| Shapovalov Y, Benavidez D, Zuch D, et al.
proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. [JOURNAL ARTICLE]
Int J Cancer 2009 Nov 5.
Abstract | Full Citation |
| Petruzziello F, Zeppa P, Catalano L, et al.
Amyloid in bone marrow smears of patients affected by multiple myeloma. [JOURNAL ARTICLE]
Ann Hematol 2009 Nov 6.
Abstract | Full Citation | Find Related Articles |
| Vahdat AM, Reiners KS, Simhadri VL, et al.
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. [JOURNAL ARTICLE]
Leukemia 2009 Nov 5.
Abstract | Full Citation | Find Related Articles |
| Stegall MD, Gloor JM
Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. [JOURNAL ARTICLE]
Curr Opin Organ Transplant 2009 Nov 3.
Abstract | Full Citation | Find Related Articles |
| Bernardeschi P, Pirrotta MT, Montenora I, et al.
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record. [LETTER]
Leuk Res 2009 Nov 2.
Full Citation | Find Related Articles |
| Zhou Y, Garcia MK, Chang DZ, et al.
Multiple Myeloma, Painful Neuropathy, Acupuncture? [JOURNAL ARTICLE]
Am J Clin Oncol 2009 Jun; 32(3):319-325.
Abstract | Full Citation |
| Rzymski T, Milani M, Singleton DC, et al.
Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. [JOURNAL ARTICLE]
Cell Cycle 2009 Dec 15; 8(23)
Abstract | Full Citation | Find Related Articles |
| Serefhanoglu S, Haznedaroglu IC, Goker H, et al.
Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. [Journal Article]
Onkologie 2009 Nov; 32(11):662-4.
Abstract | Full Citation | Find Related Articles |
| Foti C, Florean C, Pezzutto A, et al.
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Nov 3.
Abstract | Full Citation | Find Related Articles |
| Roussel M, Moreau P, Huynh A, et al.
Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroupe Francophone du Myelome (IFM). [JOURNAL ARTICLE]
Blood 2009 Nov 2.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
  |
